目的 观察扶正安中汤联合卡培他滨对气阴两虚型三阴性乳腺癌（TNBC）术后患者的治疗效果。方法 选 择 2022 年 8 月至 2023 年 8 月在广东省第二中医院接受治疗的 60 例气阴两虚型 TNBC 术后患者作为研究对象，随机分为观察组和对照组，每组 30 例。对照组给予卡培他滨治疗，观察组在对照组的基础上加用扶正安中汤治疗，疗程为 4 周。观察 2 组患者治疗前后中医证候积分、血清肿瘤标志物及白细胞计数（WBC）、血小板计数（PLT）、血红蛋白（HGB）水平的变化情况，并评价 2 组患者的临床疗效与治疗安全性。结果 （1）治疗后，观察组的中医证候积分较治疗前明显降低（P＜0.05），对照组的中医证候积分有降低趋势，但差异无统计学意义（P＞0.05）；治疗后组间比较，观察组的中医证候积分明显低于对照组（P＜0.05）。（2）治疗后，2 组患者的血清肿瘤标志物癌胚抗原（CEA）、糖蛋白 125（CA125）、糖蛋白 153（CA153）水平均较治疗前明显降低（P＜0.05），且观察组的 CEA、CA125、CA153 水平明显低于对照组（P＜0.05）。（3）治疗后，对照组的 WBC、HGB、PLT 水平均较治疗前明显降低（P＜0.05），观察组的 WBC、HGB、PLT 水平有降低趋势，但差异均无统计学意义（P＞ 0.05）；治疗后组间比较，观察组的 WBC、HGB、PLT 水平高于对照组（P＜0.05）。（4）观察组的总有效率为 90.00% （27/30），明显高于对照组的 33.33% （10/30）（P＜0.05）；观察组的不良反应发生率（16.67%）明显低于对照组（43.33%）（P＜0.05）。结论 扶正安中汤联合卡培他滨治疗能够提高气阴两虚型 TNBC 术后患者的临床疗效，有效改善患者的临床症状，降低肿瘤标志物水平，减轻化疗药物毒副作用，安全性较高。

Objective To observe the therapeutic effect of Fuzheng Anzhong Decoction combined with capecitabine on postoperative patients with triple-negative breast cancer （TNBC）of qi-yin deficiency type. Methods A total of 60 TNBC postoperative patients with qi-yin deficiency type，who received treatment in Guangdong Second of Traditional Chinese Medicine Hospital from August 2022 to August 2023， were selected as the study objects and randomly divided into observation group and control group，with 30 cases in each group. The control group was treated with capecitabine，and the observation group was treated with Fuzheng Anzhong Decoction on the basis of treatment for the control group. The courses of treatment covered four weeks. The changes of traditional Chinese medicine （TCM） syndrome scores，serum levels of tumor markers，white blood cell （WBC） count，platelet （PLT） count and hemoglobin （HGB） level of the two groups were observed. The clinical efficacy and safety of the two groups were evaluated. Results （1） After treatment，the TCM syndrome score of the observation group was significantly lower than that before treatment （P＜0.05）， while the TCM syndrome score of the control group showed a decreasing trend， but the difference was not statistically significant （P＞0.05）. The TCM syndrome score of the observation group was significantly lower than that of the control group by the comparison between two groups after treatment （P＜0.05）. （2） After treatment， the levels of serum tumor markers， namely carcinoembryonic antigen （CEA）， glycoprotein 125 （CA125）， and glycoprotein 153 （CA153） in both groups were significantly lower than those before treatment （P＜0.05），and the levels of CEA，CA125，and CA153 in the observation group were significantly lower than those in the control group （P＜0.05）. （3） After treatment，the levels of WBC，HGB，and PLT in the control group were significantly decreased compared with those before treatment （P＜0.05），whereas the levels of WBC，HGB，and PLT in the observation group demonstrated a downward tendency，but without statistical significance （P＞0.05） . After treatment，the levels of WBC， HGB， and PLT in the observation group were higher than those in the control group by the comparison between two groups after treatment （P＜0.05）. （4） The total effective rate of 90.00% （27/30） in the observation group was significantly higher than that of 33.33% （10/30） in the control group （P＜0.05）. The incidence of adverse reactions in observation group （16.67%） was significantly lower than that in control group （43.33%）（P＜0.05）. Conclusion Fuzheng Anzhong Decoction in combination with capecitabine can enhance the clinical efficacy of postoperative TNBC patients with qi-yin deficiency type，effectively alleviate the clinical symptoms of patients，lower the level of tumor markers，reduce the toxic and side effects of chemotherapy drugs，and exhibit high safety.

R273.379

广东省中医药局科研项目（202205042033413760）